 The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. Immunoglobulin M IgM and immunoglobulin A IgA are classes of antibodies naturally produced 